Meeting
2017 ASCO Annual Meeting
Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.
Authors
Lajos Pusztai
Yale Cancer Center, New Haven, CT
Lajos Pusztai , Andrea Silber , Erin Wysong Hofstatter , Gina G. Chung , Nina Ruth Horowitz , Donald R. Lannin , Brigid K. Killelea , Anees B. Chagpar , Borbala Szekely , Courtney Frederick , Lawrence Rispoli , Michael DiGiovanna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT02489448
Citation
J Clin Oncol 35, 2017 (suppl; abstr 572)
DOI
10.1200/JCO.2017.35.15_suppl.572
Abstract #
572
Poster Bd #
172
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
First Author: Lajos Pusztai
Poster
2022 ASCO Annual Meeting
Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.
First Author: Julia Foldi
Poster
2021 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.
First Author: Shigehira Saji
Poster
2018 ASCO Annual Meeting
Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.
First Author: Xiaotong Li